PT  - JOURNAL ARTICLE
AU  - Rambasek, Todd E.
AU  - Lang, David M.
AU  - Kavuru, Mani S.
TI  - Omalizumab: Where does it fit into current asthma management?
DP  - 2004 Mar 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 251--261
VI  - 71
IP  - 3
4099  - http://www.ccjm.org/content/71/3/251.short
4100  - http://www.ccjm.org/content/71/3/251.full
SO  - Cleve Clin J Med2004 Mar 01; 71
AB  - Omalizumab (Xolair), a monoclonal antibody, is a new agent that blocks the allergic cascade at its primary step. This drug offers substantial promise for patients with moderate-to-severe, persistent allergic asthma that is not well controlled. But due to the cost of the drug, limitations on dosage, and available clinical trial data, it is not a first-line therapy. This review discusses how this drug works, which patients will be candidates for it, and the practical aspects of using it.